Stockscreener 앱 받기
16.05
1.97%
0.31
시간 외 거래:
15.91
-0.14
-0.87%
전일 마감가:
$15.74
열려 있는:
$15.69
하루 거래량:
11.02M
Relative Volume:
1.27
시가총액:
$18.49B
수익:
$14.33B
순이익/손실:
$-3.79B
주가수익비율:
-5.0631
EPS:
-3.17
순현금흐름:
$1.84B
1주 성능:
-0.50%
1개월 성능:
+24.81%
6개월 성능:
+50.99%
1년 성능:
+47.79%
1일 변동 폭
$15.60
$16.07
1주일 범위
$15.59
$16.30
52주 변동 폭
$6.85
$16.30
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.05 | 18.13B | 14.33B | -3.79B | 1.84B | -3.17 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.54 | 57.69B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
129.13 | 53.00B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.22 | 50.01B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.11 | 40.08B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.05 | 20.77B | 3.13B | 1.27B | 1.12B | 26.39 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - Insider Monkey
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
(VTRS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Viatris Inc (VTRS) May Struggle to Outperform: A Look at Fut - GuruFocus
How Do Investors Really Feel About Viatris Inc? - Sahm
Can Viatris Inc. sustain its profitabilityJuly 2025 Levels & Daily Chart Pattern Signals - mfd.ru
Where is Viatris Inc. (VTRS) headed according to the Street? - MSN
Is Viatris Inc. impacted by rising ratesWeekly Trend Summary & Technical Confirmation Alerts - mfd.ru
Is Viatris (VTRS) Quietly Repositioning Its Deal-Making Strategy With a New Chief Legal Officer? - simplywall.st
Viatris (VTRS) Shares Cross 3% Yield Mark - Nasdaq
Viatris Continues Support of SBP, Celebrates Restoration of 250th Home Damaged by Hurricane Maria - CSRwire
Viatris Inc. stock rises Monday, outperforms market - MSN
JPMorgan Adjusts Price Target on Viatris to $16 From $14, Maintains Neutral Rating - marketscreener.com
Viatris stock hits 52-week high at $15.61 By Investing.com - Investing.com Australia
Chris Davis's Strategic Acquisition of Viatris Inc. Shares - GuruFocus
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse - FinancialContent
Viatris stock hits 52-week high at $15.61 - Investing.com
Indiana wins $6.25 million in settlement with pharmaceutical companies - starcitytv.com
Where is Viatris Inc. (VTRS) Headed According to the Street? - Finviz
Viatris Septerna BIO Takeda name new legal chiefs - BioXconomy
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS) - The Globe and Mail
Viatris 2022 Sustainability Report: Building Foundations To Advance Diversity, Equity and Inclusion - CSRwire
Why Viatris (VTRS) Stock Is Up Today - The Globe and Mail
Viatris Stock Hits 52-Week High After UBS Buy Rating & $18 Price Target | Market Update 2026News and Statistics - IndexBox
Why Viatris (VTRS) Shares Are Rising Today - Bitget
Viatris gains as UBS upgrades to buy on outlook and pipeline - MSN
Indiana reaches $6.25M settlement with pharmaceutical companies over EpiPen prices - Indianapolis Business Journal
Viatris gains as UBS upgrades to Buy (VTRS:NASDAQ) - Seeking Alpha
US drugmaker Viatris appoints in-house pharma veteran as next CLO - The Global Legal Post
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Viatris to Buy From Neutral, Adjusts Price Target to $18 From $11 - marketscreener.com
A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment - Yahoo Finance
Is Viatris’ New Deal-Tested CLO a Turning Point in Its Transformation Strategy (VTRS)? - simplywall.st
Responsive Playbooks and the VTRS Inflection - Stock Traders Daily
Inflation Data: Is Viatris Inc impacted by rising ratesMarket Activity Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
What are Wall Street analysts' target price for Viatris stock? - MSN
Viatris Announces Chief Legal Officer Transition and Successor - The Globe and Mail
Viatris Inc (VTRS) Stock Price Up 5.3% on Feb 4 - GuruFocus
Viatris Appoints Matthew J. Maletta as Chief Legal Officer - The Malaysian Reserve
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026 - Sahm
Viatris to Report Fourth Quarter and Full Year 2025 Financial Re - GuruFocus
Viatris stock hits 52-week high at $13.49 By Investing.com - Investing.com Nigeria
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
1.05%
자본화:
|
볼륨(24시간):